surpass cvot tirzepatide results Effects of on adjudicated cardiovascular events in 💡 New insight in diabetes

Our findings, combined with existing evidence, suggest that semaglutide and perhaps other GLP1-RAs should be reconceptualized as disease-modifying treatments rather than solely medications for glycaemic control or weight loss, concluded the authors

Hepatology 51:445453 Torres DM, Jones FJ, Shaw JC et al (2011) Rosiglitazone versus rosiglitazone and metformin versus rosiglitazone and losartan in the treatment of nonalcoholic steatohepatitis in humans: a 12-month randomized, prospective, open- label trial

Both doses of 10 mg and 25 mg had similar hazard ratios for cardiovascular outcomes

Each batch is analytically tested to ensure purity and consistency for experimental applications